Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' SOLAR-1 Study Shines on Alpelisib In Breast Cancer

Executive Summary

The selective PI3K inhibitor, alpelisib, met its primary PFS endpoint in top-line data from the SOLAR-1 study, but further details are needed from the trial in order to judge the drug's likely penetration of the HR-positive, HER2-negative breast cancer population.

You may also be interested in...



Novartis's Piqray Gets Europe Green Light At Last

It has taken a while but European regulators have finally followed their US counterparts and approved Piqray, making it the first targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation.

Key Cancer Data To Be Unveiled At ESMO In Munich

Big pharma and little biotechs are getting ready to pack their bags for Germany where over 2,000 abstracts will be presented at ESMO and the fine details on some major oncology studies will be closely watched.

Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta

Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel